References
- Chaigne B, Watier H. Theranostic of biopharmaceuticals. P Pharmacol Ther 2017 Feb 13. pii: S0163-7258(17)30049-9. PMID:28223229; https://doi.org/10.1016/j.pharmthera.2017.02.035
- Pèlegrin A, Daguet A, Watier H. MAbImprove: A French ‘Laboratoire d'excellence’ (LabEx) dedicated to therapeutic antibodies. mAbs 2014; 6(4):803-4; PMID:24842678; https://doi.org/10.4161/mabs.29262
- Beck A, Reichert JM. Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 2012; 4(4):419-25; PMID:22699226; https://doi.org/10.4161/mabs.20996
- Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: First global approval. Drugs 2012; 72(9):1293-8; PMID:22686619; https://doi.org/10.2165/11631090-000000000-00000
- Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2010; 2(6):594-606; PMID:20864805; https://doi.org/10.4161/mabs.2.6.13420
- Errey JC, Doré AS, Zhukov A, Marshall FH, Cooke RM. Purification of Stabilized GPCRs for Structural and Biophysical Analyses. Methods Mol Biol Clifton NJ 2015; 1335:1-15; PMID:26260590; https://doi.org/10.1007/978-1-4939-2914-6_1
- Kean J, Bortolato A, Hollenstein K, Marshall FH, Jazayeri A. Conformational thermostabilisation of corticotropin releasing factor receptor 1. Sci. Rep 2015; 5:11954; PMID:26159865; https://doi.org/10.1038/srep11954
- Hollenstein K, Kean J, Bortolato A, Cheng RK, Doré AS, Jazayeri A, Cooke RM, Weir M, Marshall FH. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013; 499(7459):438-43; PMID:23863939; https://doi.org/10.1038/nature12357
- Cooke RM, Koglin M, Errey JC, Marshall FH. Preparation of purified GPCRs for structural studies. Biochem Soc Trans 2013; 41(1):185-90; PMID:23356281; https://doi.org/10.1042/BST20120240
- Slack RJ, Russell LJ, Barton NP, Weston C, Nalesso G, Thompson SA, Allen M, Chen YH, Barnes A, Hodgson ST, et al. Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor. Pharmacol Res Perspect 2013; 1(2):e00019; PMID:25505571; https://doi.org/10.1002/prp2.19
- Jazayeri A, Marshall F. Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. Expert Rev Neurother 2015; 15(2):123-5; PMID:25578566; https://doi.org/10.1586/14737175.2015.1001369
- Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011; 477(7366):549-55; PMID:21772288; https://doi.org/10.1038/nature10361
- Hutchings CJ, Cseke G, Osborne G, Woolard J, Zhukov A, Koglin M, Jazayeri A, Pandya-Pathak J, Langmead CJ, Hill SJ, et al. Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. mAbs 2014; 6(1):246-261; PMID:24253107; https://doi.org/10.4161/mabs.27226
- Rossant CJ, Carroll D, Huang L, Elvin J, Neal F, Walker E, Benschop JJ, Kim EE, Barry ST, Vaughan TJ. Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes. mAbs 2014; 6(6):1425-38; PMID:25484064; https://doi.org/10.4161/mabs.34376
- Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, Ek M, Sjögren T, Rider D, Privezentzev C, et al. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. mAbs 2015; 7(1):152-166; PMID:25484051; https://doi.org/10.4161/19420862.2014.985158
- Bourquard T, Landomiel F, Reiter E, Crépieux P, Ritchie DW, Azé J, Poupon A. Unraveling the molecular architecture of a G protein-coupled receptor/β-arrestin/Erk module complex. Sci Rep 2015; 5:10760; PMID:26030356; https://doi.org/10.1038/srep10760
- Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U A 2010; 107:20565-70; PMID:21059953; https://doi.org/10.1073/pnas.1012865107
- Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, Leurs R. Pharmacological modulation of chemokine receptor function. Br J Pharmacol 2012; 165:1617-43; PMID:21699506; https://doi.org/10.1111/j.1476-5381.2011.01551.x
- Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 2013; 288:29562-72; PMID:23979133; https://doi.org/10.1074/jbc.M113.498436
- Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, Van den Heede K, Roobrouck A, Grot E, Kent TC, et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol 2015; 87:251-262; PMID:25468882; https://doi.org/10.1124/mol.114.094821
- Mujić-Delić A, de Wit RH, Verkaar F, Smit MJ. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics. Trends Pharmacol Sci 2014; 35(5):247-55; PMID:24690241; https://doi.org/10.1016/j.tips.2014.03.003
- Rondard P, Pin JP. Dynamics and modulation of metabotropic glutamate receptors. Curr Opin Pharmacol 2015; 20:95-101; PMID:25529199; https://doi.org/10.1016/j.coph.2014.12.001
- Claes K, Vandewalle K, Laukens B, Laeremans T, Vosters O, Langer I, Parmentier M, Steyaert J, Callewaert N. Modular integrated secretory system engineering in Pichia pastoris To enhance G-Protein coupled receptor expression. ACS Synth Biol 2016; 5:1070-5; PMID:27176489; https://doi.org/10.1021/acssynbio.6b00032
- Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, Steyaert J, Parmentier M, Langer I. Development by genetic immunization of monovalent antibodies (Nanobodies) behaving as antagonists of the human ChemR23 receptor. J Immunol 2016; 196:2893-901; PMID:26864035; https://doi.org/10.4049/jimmunol.1500888